Zogenix (ZGNX) Misses Q4 EPS by 20c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results
March 2, 2020 4:01 PM ESTNDA for FINTEPLA® in Dravet syndrome accepted for review by FDA; new PDUFA target acion date of June 25, 2020Two-year interim analysis of FINTEPLA open-label extension study in Dravet syndrome patients demonstrated a 77% and 83% reduction in median convulsive seizure frequency at one and two years, respectivelyGlobal Phase 3 study of FINTEPLA in Lennox-Gastaut syndrome achieved primary drop seizure reduction endpoint with high statistical significance
EMERYVILLE, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today provided a corporate... More
